if channel

Calcium Channel antagonist 4 is a voltage-gated calcium channel inhibitor (IC50 : 5-20 μM).

Ca2+ channel agonist 1 is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2 (EC50s: 14.23 μM and 3.34 μM) and is used as a potential treatment for motor nerve terminal dysfunction.

M2 ion channel blocker ,Antiviral agent, is capable of inhibiting and blocking the activity of M2 ion channel.

N-type calcium channel blocker-1 is an orally active analgesic agent with a high affinity for functionally blocking N-type calcium channels.

Sodium Channel inhibitor1 is a novel and selective voltage-gated sodium channel for pain treatment. (IC50 Value of 0.16 uM and 0.41 uM for Na v1.7, V hold-90mV and Na v1.7, V hold-90mV)

Sodium Channel Inhibitor 2 [Sodium Channel inhibitor 2] is a blocker of sodium channels.

Calcium Channel antagonist5 (compound 32) is a calcium channel antagonist with a pIC50 of 5.50.

Sodium Channel inhibitor5 (compound 7d) is a potent sodium channel inhibitor with an IC50 of 2.7 μM, playing a significant role in antiarrhythmic research.

Calcium Channel antagonist6 (Compound 328) is a highly selective antagonist of the voltage-gated calcium channel CaV2.2, with an IC50 of 0.37 μM. It inhibits calcium ion influx caused by neuronal depolarization and shows potential for research in neuropathic pain.

KCa2 channel modulator 1 (compound 2o) is an effective, subtype-selective K/Ca2 channel positive modulator that potentiates rat KCa2.2 channels with an EC50 value of 0.99 μM and human KCa2.3 channels with an EC50 value of 0.19 μM [1].

KCa2 channel modulator 2 (compound 2q) is an effective, subtype-selective K/Ca 2 channel positive modulator with similar potency on the human K Ca 2.3 channel and rat K Ca 2.2a subtypes, exhibiting EC50 values of 0.60 μM and 0.64 μM, respectively [1].

SK3 Channel-IN-1 (compound 7a) is a potent and selective SK3 channel modulator that effectively inhibits breast cancer MDA-MB-435 cell migration with low cytotoxicity in other cell lines, and it modulates ion channel activity in cancer cells [1].

T-Type calcium channel inhibitor 2 (compound 6g) is a potent inhibitor of the T-type calcium channel, specifically acting on Cav3.1 (α1G) with an IC50 of 31.0 μM, Cav3.2 (α1H) with an IC50 of 83.1 μM, and Cav3.3 (α1I) (α1H). T-Type calcium channel inhibitor 2 exhibited cytotoxicity against A549 and HCT-116 cells with IC50s of 5.0 μM and 6.4 μM, respectively.

KCa1.1 Channel Activator-1, a hybrid derivative of Quercetin, selectively stimulates the vascular KCa1.1 channels while also blocking CaV1.2 channels. Additionally, it demonstrates weak myorelaxant activity.

KCa1.1 channel activator-2, a hybrid derivative of Quercetin, selectively stimulates the vascular KCa1.1 channels. This compound demonstrates significant myorelaxant activity.

Calcium Channel antagonist 2 is a calcium channel antagonist (IC50=5-20 μM) that can be used to study diseases due to Ca2+ channels like pain and diabetes.

Nav1.3 Channel Inhibitor 1 (Compound 15b) is a state-dependent inhibitor of the voltage-gated sodium channel Na v 1.3, with an IC50 value of 20 nM. It has the ability to cross the blood-brain barrier, making it applicable for research into nervous system disorders [1].

Sodium Channel Inhibitor 4 is a compound that functions as a sodium channel inhibitor [1].

Kv3 channel protein is expressed by parvalbumin (PV)-containing pallidal neurons.Kv3, Channel Containing Protein (567-585) corresponds to amino acids 567 to 585 fragment of the Kv3.1b channel containing protein.

Kv3, Channel Containing Protein (567-585) refers to the amino acid peptide sequence spanning residues 567 to 586 of the Kv3.1b channel protein. The Kv3 channel protein is expressed in neurons within the globus pallidus, known for containing PV protein.

YM758 is an inhibitor of If current channel.

Ivabradine hydrochloride (S 16257-2) is a new If inhibitor (IC50: 2.9 μM). Ivabradine Hydrochloride is the hydrochloride salt form of ivabradine, an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker, with negative chronotropic activity. Upon administration, ivabradine selectively binds to the intracellular portion of the HCN channel pore and blocks HCN channels in the pacemaker cells within the sinoatrial (SA) node. This inhibits the If (funny) pacemaker ion current, prevents the inward flow and intracellular accumulation of positively charged ions, reduces pacemaker activity and slows diastolic depolarization.

Cilobradine hydrochloride (DK-AH 269) is an HCN Channel blocker and an open channel blocker of neuronal Ih and related cardiac If channels.

Ivabradine is a potent, orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits pacemaker current (If). ivabradine decreases heart rate in a dose-dependent manner and does not alter blood pressure. ivabradine has anticonvulsant, anti-ischaemic and anti-anginal effects.